


NDB

## Chemical Properties

|                   |  |
|-------------------|--|
| CAS No. :         | 1660153-08-1   |
| Formula:          | C <sub>26</sub> H <sub>28</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>2</sub>  |
| Molecular Weight: | 471.42   |
| Storage:          | Store at low temperature<br>Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br><i>Actual storage temperature shall be subject to the COA.</i> |



## Biological Description

|               |   |
|---------------|---|
| Description   | NDB is a selective and potent hFXR $\alpha$ antagonist that inhibits GW4064-stimulated FXR/RXR interactions and FXR $\alpha$ target gene expression in primary mouse hepatocytes. NDB is used in the study of diabetes.   |
| Targets(IC50) | FXR   |
| In vitro      | NDB induces rearrangements of helix 11 (H11) and helix 12 (H12, AF-2) by forming a homodimer of hFXR $\alpha$ -LBD, differing significantly from the active monomer conformation [1]. At 25 $\mu$ M, NDB effectively antagonizes the GW4064-stimulated FXR/RXR interaction and FXR $\alpha$ target gene expression in primary mouse hepatocytes, including the small heterodimer partner (SHP) and bile-salt export pump (BSEP)[1]. |
| In vivo       | Administered through intraperitoneal injection at a dosage of 24 mg/kg once a day for a duration of 4 weeks, NDB efficiently decreases the gene expressions of phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-phosphatase (G6-pase), small heterodimer partner, and bile-salt export pump (BSEP) in db/db mice[1].  |

## Solubility Information

|                     |  |
|---------------------|--|
| Solubility          | DMSO: 80 mg/mL (169.7 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)  |
| In vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (7 mM),Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | 1mg       | 5mg        | 10mg       |
|-------|-----------|------------|------------|
| 1 mM  | 2.1213 mL | 10.6063 mL | 21.2125 mL |
| 5 mM  | 0.4243 mL | 2.1213 mL  | 4.2425 mL  |
| 10 mM | 0.2121 mL | 1.0606 mL  | 2.1213 mL  |
| 50 mM | 0.0424 mL | 0.2121 mL  | 0.4243 mL  |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Xu X, et al. Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor  $\alpha$  (FXR $\alpha$ ) in Stabilizing the Homodimerization of the Receptor. *J Biol Chem.* 2015 Aug 7;290(32):19888-99.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481